Verity & Verity LLC Has $31.46 Million Stock Holdings in Gilead Sciences, Inc. $GILD

Verity & Verity LLC lessened its stake in Gilead Sciences, Inc. (NASDAQ:GILD) by 13.4% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 283,778 shares of the biopharmaceutical company’s stock after selling 43,792 shares during the quarter. Gilead Sciences makes up about 2.7% of Verity & Verity LLC’s holdings, making the stock its 6th largest position. Verity & Verity LLC’s holdings in Gilead Sciences were worth $31,463,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in Gilead Sciences by 1.6% during the 2nd quarter. Vanguard Group Inc. now owns 119,364,226 shares of the biopharmaceutical company’s stock worth $13,233,912,000 after acquiring an additional 1,893,401 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Gilead Sciences by 2.6% during the second quarter. Geode Capital Management LLC now owns 29,207,662 shares of the biopharmaceutical company’s stock worth $3,231,548,000 after purchasing an additional 727,515 shares during the last quarter. Price T Rowe Associates Inc. MD grew its position in Gilead Sciences by 314.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 14,703,103 shares of the biopharmaceutical company’s stock worth $1,647,484,000 after purchasing an additional 11,156,382 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Gilead Sciences by 12.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 13,755,481 shares of the biopharmaceutical company’s stock valued at $1,541,302,000 after buying an additional 1,520,809 shares during the last quarter. Finally, Nuveen LLC bought a new position in shares of Gilead Sciences during the 1st quarter worth approximately $620,415,000. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several research firms have recently issued reports on GILD. Rothschild & Co Redburn upped their target price on Gilead Sciences from $143.00 to $153.00 in a report on Monday, November 10th. Wells Fargo & Company upped their price objective on Gilead Sciences from $140.00 to $145.00 and gave the company an “overweight” rating in a research note on Friday, October 31st. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $145.00 to $150.00 and gave the stock an “overweight” rating in a report on Friday, October 31st. Wolfe Research boosted their target price on shares of Gilead Sciences from $135.00 to $140.00 and gave the company an “outperform” rating in a research note on Thursday, October 23rd. Finally, Mizuho lifted their price target on shares of Gilead Sciences from $131.00 to $140.00 and gave the stock an “outperform” rating in a report on Friday. Two analysts have rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and three have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Gilead Sciences currently has an average rating of “Moderate Buy” and a consensus price target of $130.65.

Insiders Place Their Bets

In other news, CEO Daniel Patrick O’day sold 10,000 shares of Gilead Sciences stock in a transaction dated Tuesday, October 28th. The stock was sold at an average price of $119.39, for a total transaction of $1,193,900.00. Following the completion of the sale, the chief executive officer owned 581,203 shares in the company, valued at approximately $69,389,826.17. This trade represents a 1.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $125.23, for a total transaction of $313,075.00. Following the completion of the transaction, the chief financial officer directly owned 154,555 shares in the company, valued at $19,354,922.65. The trade was a 1.59% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 125,146 shares of company stock worth $15,148,441. Insiders own 0.27% of the company’s stock.

Gilead Sciences Price Performance

GILD opened at $125.94 on Tuesday. The firm has a 50-day moving average price of $118.73 and a 200-day moving average price of $113.94. Gilead Sciences, Inc. has a twelve month low of $88.57 and a twelve month high of $128.70. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13. The company has a market capitalization of $156.26 billion, a price-to-earnings ratio of 25.10, a PEG ratio of 0.81 and a beta of 0.32.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Thursday, October 30th. The biopharmaceutical company reported $2.47 EPS for the quarter, topping the consensus estimate of $2.16 by $0.31. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.77 billion during the quarter, compared to the consensus estimate of $7.42 billion. During the same period last year, the firm earned $2.02 EPS. Gilead Sciences’s revenue for the quarter was up 3.0% on a year-over-year basis. Gilead Sciences has set its FY 2025 guidance at 8.050-8.250 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 30th. Shareholders of record on Monday, December 15th will be issued a $0.79 dividend. The ex-dividend date of this dividend is Monday, December 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.5%. Gilead Sciences’s dividend payout ratio (DPR) is presently 48.99%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.